We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
EPTN

European Particle Therapy Network (EPTN)

The European Particle Therapy Network (EPTN) became a task force of ESTRO in 2017. It was established in 2015 in response to the anticipated increase in the number of particle therapy centres in Europe. In addition, the need to cooperate among centres and integrate particles (i.e. protons and carbons) in the framework of clinical research networks was identified as being of paramount importance. ESTRO, at the time of initiation of the network, was asked to collaborate with EPTN and agreed to facilitate the group.

Particle therapy (PT) is only one part of radiation oncology, and needs to be well aligned with other radiation techniques as well as with general developments in cancer research and patient care. PT offers both new opportunities for providing excellence in cancer care, and for high-quality research within the framework of European  networks.

8th European Particle Therapy Network (EPTN) WORKSHOP
5 October 2022, Leuven, Belgium
Particle Therapy Interuniversity Centre Leuven, Leuven, Belgium
https://www.uzleuven.be/en/proton-centre/collaboration-proton-centre-particle

 

The programme will be available soon.

Registration for the workshop is obligatory.

To register for the workshop on a complimentary basis, please fill in the registration form.

Registration form

The workshop will be limited to 100 participants. Registration will be on a ‘first come, first serve’ basis.

Registration Deadline 21 September 2022

For queries regarding the workshop please contact eptn@estro.org

The EPTN has three organisers and is composed of 7 working parties (WP) with experts for different topics to further elaborate the particle European discussions. It meets once a year.

EPTN organisers:

  • Cai Grau (Aarhus, DK) 

  • Damien Weber (Villigen, CH) 

  • Dietmar Georg (Vienna, AT)

WP

Title

Coordinators

1

Clinical

Hans Langendijk (Groningen, NL)-Leader

Roberto Orecchia (Milano, IT)

Karin Hausterman (Leuven, BE)

Daniel Zips (Berlin, DE)

Jacques Balosso (Grenoble, FR)

Esther Troost (Dresden, DE)

2

Dose assessment, quality assurance, dummy runs, technology inventory

Oliver Jäkel (Heidelberg, DE)

Sairos Safai (Villigen, CH)

Stefano Lorentini (Trento, IT)

3

Education 

Morten Høyer (Aarhus, DK)

Marco Schwarz (Trento, IT)

4

Image Guidance in particle therapy

Aswin Hoffmann (Dresden, DE)

Alessandra Bolsi (Villigen, CH)

5

TPS in particle therapy

WP5 Collective PTPS specifications

Håkan Nyström (Uppsala, SE)

Tony Lomax (Villigen, CH)

6

Radiobiology, RBE

Manjit Dosanjh (Geneva, CH)

Bleddyn Jones (Oxford, UK)

Armin Lühr (Dortmund, Germany)

Jörg Pawelke (Dresden, DE)

Martin Pruschy (Zurich, CH)

Brita S. Sørensen (Aarhus, DK

7

Health Economy

Yolande Lievens (Ghent, BE)

 

EPTN Reports

EPTN Documents

  • Eekers DBP et al. Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology. Radiother Oncol 2021; 160: 259-265, 2021 https://doi.org/10.1016/j.radonc.2021.05.013
  • Sørensen BS, et al. Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy? Radiother Oncol 2021;163:177–84. https://doi.org/10.1016/j.radonc.2021.08.016
  • Heuchel L, et al. Is a variable proton RBE considered in clinical practice? - ESTRO survey among 25 proton centres. Radiother Oncol 161(Suppl.1) (2021) S313-314, DOI: 10.1016/S0167-8140(21)06904-8

  • De Roeck L, et al. The European particle therapy network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation. Radiother Oncol. 2022 Jan 27:S0167-8140(22)00021-4. https://doi.org/10.1016/j.radonc.2022.01.018

  • Heuchel L, et al. Clinical use and future requirements of relative biological effectiveness: Survey among all European proton therapy centres. Radiother Oncol 2022; 172, P134-139, July 01, 2022
    https://doi.org/10.1016/j.radonc.2022.05.015